AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14960293 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study 11111813 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 24
Study 11111813 — intervention group
Group type: COMPARATOR
Intervention: Biseko (standardized serum protein solution)
Number of subjects: 24
Study 9443168 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 884
Study 9443168 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 884
Study 9443168 — intervention group
Group type: COMPARATOR
Intervention: Betahistine
Number of subjects: 884
Study 8329259 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol 2.5 mg kg‐1
Number of subjects: 41
Study 8329259 — intervention group
Group type: COMPARATOR
Intervention: thiopentone 5.0 mg kg‐1
Number of subjects: 41
Study 3296355 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT recipients (21 participants)
Number of subjects: 96
Study 3296355 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic BMT recipients (56 participants)
Number of subjects: 96
Study 30470646 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT (25μg for women, 50μg for men)
Number of subjects: 462
Study 30470646 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT
Number of subjects: 462
Study 30470646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 29889060 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback postural training using Lumo Lift for three weeks
Number of subjects: 31
Study 29889060 — intervention group
Group type: COMPARATOR
Intervention: Control group wore a pedometer to track physical activity
Number of subjects: 31
Study 27788457 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive imagery manipulation
Number of subjects: 42
Study 27788457 — intervention group
Group type: COMPARATOR
Intervention: Neutral imagery manipulation
Number of subjects: 42
Study 24622426 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure group
Number of subjects: 156
Study 24622426 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure group
Number of subjects: 156
Study 24622426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study 22318208 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention designed to improve hypertension knowledge, disease self-management behaviors, and health outcomes
Number of subjects: 219
Study 20236406 — intervention group
Group type: EXPERIMENTAL
Intervention: Program 1
Number of subjects: 1292
Study 20236406 — intervention group
Group type: EXPERIMENTAL
Intervention: Program 2
Number of subjects: 1292
Study 20236406 — intervention group
Group type: EXPERIMENTAL
Intervention: Program 1 and Program 2
Number of subjects: 1292
Study 18236300 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 32
Study 18236300 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 32
Study 15934450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mand-elicited imitation (MEI)
Number of subjects: 29
Study 15934450 — intervention group
Group type: COMPARATOR
Intervention: Modeling with auditory bombardment (Mod-AB)
Number of subjects: 29
Study 15934450 — intervention group
Group type: COMPARATOR
Intervention: Both MEI and Mod-AB
Number of subjects: 29
Study 14569237 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month endurance and strength training program
Number of subjects: 15
Study 14569237 — intervention group
Group type: COMPARATOR
Intervention: Nontrained subjects (control group)
Number of subjects: 15
Study 10642369 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (5 g Cr monohydrate + 20 g glucose) four times per day for 5 days
Number of subjects: 15
Study 8697183 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mM HCl (pH 1)
Number of subjects: 9
Study 8697183 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaCl (1711 mOsm/kg)
Number of subjects: 9
Study 8697183 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile
Number of subjects: 9
Study 8697183 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-osmolar sodium oleate
Number of subjects: 9
Study 8697183 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (Control)
Number of subjects: 9
Study 8697183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL bolus of any solution
Number of subjects: 9
Study 7971477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tris (pH = 10.5) intravenous infusion followed by hyperventilation
Number of subjects: 39
Study 7971477 — intervention group
Group type: COMPARATOR
Intervention: Chronic stable angina pectoris (control group)
Number of subjects: 39
Study 7971477 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons (control group)
Number of subjects: 39
Study 7971477 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant angina patients
Number of subjects: 39
Study 3653415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg bid for 7 days
Number of subjects: 78
Study 3653415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg bid for 7 days
Number of subjects: 78
Study 3653415 — intervention group
Group type: EXPERIMENTAL
Intervention: Epostane 200 mg qid for 7 days
Number of subjects: 78
Study 29717036 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 225
Study 29717036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 27402560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (18-month duration, 86.3% adherence)
Number of subjects: 278
Study 26159136 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing smoking cessation YOU‐TURN program
Number of subjects: 136
Study 26159136 — intervention group
Group type: COMPARATOR
Intervention: General smoking cessation program
Number of subjects: 136
Study 23953888 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin-Lidose formulation
Number of subjects: 0
Study 23953888 — intervention group
Group type: COMPARATOR
Intervention: Innovator isotretinoin formulation
Number of subjects: 0
Study 21156983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5%
Number of subjects: 64
Study 21156983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 64
Study 21156983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 15 mL each of bupivacaine 0.5% and mepivacaine 1.5%
Number of subjects: 64
Study 18949772 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 200
Study 18949772 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 200
Study 17718278 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Lactobacillus acidophilus plus Bifidobacterium infantis (3 x 10(9) CFU) bid and ORS
Number of subjects: 71
Study 17718278 — intervention group
Group type: COMPARATOR
Intervention: ORS only (Control group)
Number of subjects: 71
Study 14738180 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG biofeedback treatment
Number of subjects: 7
Study 14738180 — intervention group
Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 7
Study 10768305 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) in dosages of 100‐1,600 mg/day
Number of subjects: 292
Study 8534385 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) motor Tinel's sign
Number of subjects: 120
Study 8534385 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Tinel's sign
Number of subjects: 120
Study 8534385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EMG and clinical Tinel's sign
Number of subjects: 120
Study 8534385 — intervention group
Group type: COMPARATOR
Intervention: Nerve conduction study (NCS) values from control nerves
Number of subjects: 120
Study 8534385 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS/EMG abnormalities localized to the elbow
Number of subjects: 120
Study 2199151 — intervention group
Group type: EXPERIMENTAL
Intervention: Keith Antireflux Valve (ARV) on the sump port of a double-lumen NG tube
Number of subjects: 0
Study 2199151 — intervention group
Group type: EXPERIMENTAL
Intervention: Keith Antireflux Valve (ARV)
Number of subjects: 0
Study 749854 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (CBX)
Number of subjects: 0
Study 749854 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone plus antacids (CBX + AA)
Number of subjects: 0
Study 31279962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CTX) 50 mg daily (Arm A)
Number of subjects: 52
Study 31279962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CTX) 50 mg daily with celecoxib 400 mg twice daily (Arm B)
Number of subjects: 52
Study 31279962 — intervention group
Group type: COMPARATOR
Intervention: Control group (Arm A)
Number of subjects: 52
Study 31279962 — intervention group
Group type: COMPARATOR
Intervention: Control group (Arm B)
Number of subjects: 52
Study 28361199 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto program (experimental group)
Number of subjects: 6658
Study 28361199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no school prevention program)
Number of subjects: 6658
Study 26611120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceuticals (Armolipid Plus)
Number of subjects: 100
Study 26611120 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 100
Study 26611120 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (Nutraceuticals + Ezetimibe)
Number of subjects: 100
Study 26611120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceuticals and Ezetimibe
Number of subjects: 100
Study 24029536 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable heroin
Number of subjects: 0
Study 24029536 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable methadone
Number of subjects: 0
Study 24029536 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study 22094449 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing (DB)
Number of subjects: 29
Study 19539099 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril 5 mg/d (low-dose group)
Number of subjects: 89
Study 19539099 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril 10 mg/d (high-dose group)
Number of subjects: 89
Study 19539099 — intervention group
Group type: COMPARATOR
Intervention: ramipril (both formulations)
Number of subjects: 89
Study 16432050 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 30
Study 16432050 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg/day
Number of subjects: 30
Study 16432050 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg/day
Number of subjects: 30
Study 16432050 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg/day
Number of subjects: 30
Study 14974268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegapore wound-contact material
Number of subjects: 0
Study 11560454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole followed by oral itraconazole solution
Number of subjects: 384
Study 11560454 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amphotericin B
Number of subjects: 384
Study 9158080 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day
Number of subjects: 52
Study 9158080 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg + MPA 2.5 mg/day
Number of subjects: 52
Study 9158080 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.31 mg + MPA 2.5 mg/day
Number of subjects: 52
Study 9158080 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 9158080 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg alone or with MPA
Number of subjects: 52
Study 7850238 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method for nonchromatographic measurement of urinary lactose.
Number of subjects: 84
Study 7850238 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 babies without lactose tolerance).
Number of subjects: 84
Study 2901610 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 240
Study 2901610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 2901610 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete open drainage on admission
Number of subjects: 240
Study 31634178 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week waiting period
Number of subjects: 265
Study 31634178 — intervention group
Group type: COMPARATOR
Intervention: 11-week waiting period
Number of subjects: 265
Study 29798601 — intervention group
Group type: EXPERIMENTAL
Intervention: New tail cap (Group A)
Number of subjects: 34
Study 29798601 — intervention group
Group type: COMPARATOR
Intervention: Original tail cap (Group B)
Number of subjects: 34
Study 29798601 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of fracture healing time
Number of subjects: 34
Study 29798601 — intervention group
Group type: EXPERIMENTAL
Intervention: Klemm function evaluation
Number of subjects: 34
Study 25079560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 130
Study 25079560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-vegetable meal
Number of subjects: 130
Study 25079560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-meat/low-rice meal
Number of subjects: 130
Study 25079560 — intervention group
Group type: COMPARATOR
Intervention: Low-energy-density control meal
Number of subjects: 130
Study 22706623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (PR)
Number of subjects: 22
Study 21704953 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency electroacupuncture (120-Hz stimulation)
Number of subjects: 14
Study 21704953 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency electroacupuncture (2-Hz stimulation)
Number of subjects: 14
Study 19169336 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and aspirin (SAM)
Number of subjects: 32
Study 19169336 — intervention group
Group type: COMPARATOR
Intervention: Selenium (SM)
Number of subjects: 32
Study 16871760 — intervention group
Group type: EXPERIMENTAL
Intervention: Keto amino acids
Number of subjects: 66
Study 16871760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 12934721 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning
Number of subjects: 118
Study 12934721 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning
Number of subjects: 118
Study 10746892 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized soy extract (SOYSELECT) 400 mg/day
Number of subjects: 100
Study 10746892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10746892 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day
Number of subjects: 100
Study 8777352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI); 127 metaphase II oocytes injected.
Number of subjects: 13
Study 8777352 — intervention group
Group type: COMPARATOR
Intervention: Conventional insemination; 136 oocytes used.
Number of subjects: 13
Study 1329135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 70
Study 1329135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sankin apatite root sealer (Type II)
Number of subjects: 70
Study 1329135 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth's sealer
Number of subjects: 70
Study 1329135 — intervention group
Group type: COMPARATOR
Intervention: Gutta‐percha without sealer
Number of subjects: 70
Study 6369883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 36
Study 6369883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5 mg
Number of subjects: 36
Study 31335588 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 350
Study 31335588 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-driven PrEP
Number of subjects: 350
Study 31335588 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-driven PrEP
Number of subjects: 350
Study 31335588 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol use
Number of subjects: 350
Study 31335588 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 350
Study 31335588 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of sex partners
Number of subjects: 350
Study 31335588 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisepill data
Number of subjects: 350
Study 29343012 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment regimen (2SHRZE/6HRE) with drug replacement based on DST results, treatment duration of 12 months or more if drug resistance is present, otherwise 8 months standard treatment.
Number of subjects: 254
Study 29343012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified retreatment regimen (2HL(2)EZS/2HL(2)EZS(3)/4HL(2)E) with specific dosing based on body weight, total treatment duration of 8 months.
Number of subjects: 254
Study 29343012 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment regimen (2HREZS/6HRE) recommended by national tuberculosis program, total treatment duration of 8 months.
Number of subjects: 254
Study 26782705 — intervention group
Group type: EXPERIMENTAL
Intervention: E4 (acid unstable, droplet size 0.38 mm)
Number of subjects: 12
Study 26782705 — intervention group
Group type: COMPARATOR
Intervention: E1 (acid stable, droplet size 0.33 mm)
Number of subjects: 12
Study 24612588 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-briefing intervention
Number of subjects: 31
Study 21127899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pose cycling setup
Number of subjects: 18
Study 21127899 — intervention group
Group type: COMPARATOR
Intervention: Coaching intervention (4 × 1 h)
Number of subjects: 18
Study 21127899 — intervention group
Group type: EXPERIMENTAL
Intervention: Changed bicycle setup and pedaling technique
Number of subjects: 18
Study 19167659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (nurses only)
Number of subjects: 360
Study 19167659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (nurses and parents)
Number of subjects: 360
Study 19167659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study 16616557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C and 400 IU vitamin E daily from the second trimester until delivery
Number of subjects: 2410
Study 16616557 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo daily from the second trimester until delivery
Number of subjects: 2410
Study 14977764 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine eye drops
Number of subjects: 60
Study 14977764 — intervention group
Group type: COMPARATOR
Intervention: 0.05% levocabastine
Number of subjects: 60
Study 14977764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11783744 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐alpha‐acetylmethadol (LAAM)
Number of subjects: 69
Study 11783744 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 69
Study 11783744 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 69
Study 11783744 — intervention group
Group type: COMPARATOR
Intervention: non-opioid-treated controls
Number of subjects: 69
Study 9480618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (200 micrograms/d)
Number of subjects: 36
Study 9480618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium yeast (200 micrograms/d)
Number of subjects: 36
Study 9480618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8293297 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inositol treatment
Number of subjects: 8
Study 3318427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg per day at bedtime
Number of subjects: 139
Study 3318427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 408522 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 152
Study 408522 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base
Number of subjects: 152
Study 31680394 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab/belatacept
Number of subjects: 316
Study 31680394 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG/belatacept
Number of subjects: 316
Study 31680394 — intervention group
Group type: COMPARATOR
Intervention: rATG/tacrolimus
Number of subjects: 316
Study 31680394 — intervention group
Group type: EXPERIMENTAL
Intervention: belatacept
Number of subjects: 316
Study 30525226 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 U of abobotulinumtoxinA (ABO)
Number of subjects: 21
Study 30525226 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U of abobotulinumtoxinA (ABO)
Number of subjects: 21
Study 27809345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebilet HCT™ (nebivolol 5 mg + hydrochlorothiazide 12.5 mg tablet)
Number of subjects: 0
Study 27809345 — intervention group
Group type: COMPARATOR
Intervention: Nebilet™ (nebivolol 5 mg tablet)
Number of subjects: 0
Study 27809345 — intervention group
Group type: COMPARATOR
Intervention: Clorana™ (hydrochlorothiazide 25 mg tablet)
Number of subjects: 0
Study 26229445 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (APAP)
Number of subjects: 17
Study 26229445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 23258770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 19
Study 23258770 — intervention group
Group type: COMPARATOR
Intervention: Non-anti-angiogenic therapy (TACE)
Number of subjects: 19
Study 21173651 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency endometrial ablation
Number of subjects: 81
Study 21173651 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 81
Study 21173651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 81
Study 18486508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier and glucose
Number of subjects: 98